The current state of therapeutic and T cell-based vaccines against human papillomaviruses
• HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Yang, Andrew [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
18 |
|---|
| Übergeordnetes Werk: |
Enthalten in: AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells - Shimura, Tsutomu ELSEVIER, 2014, an international journal of molecular and cellular virology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:231 ; year:2017 ; day:2 ; month:03 ; pages:148-165 ; extent:18 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.virusres.2016.12.002 |
|---|
| Katalog-ID: |
ELV030349621 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV030349621 | ||
| 003 | DE-627 | ||
| 005 | 20230623204630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.virusres.2016.12.002 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000031.pica |
| 035 | |a (DE-627)ELV030349621 | ||
| 035 | |a (ELSEVIER)S0168-1702(16)30556-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 100 | 1 | |a Yang, Andrew |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The current state of therapeutic and T cell-based vaccines against human papillomaviruses |
| 264 | 1 | |c 2017 | |
| 300 | |a 18 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed. | ||
| 650 | 7 | |a Human papillomavirus |2 Elsevier | |
| 650 | 7 | |a Therapeutic vaccine |2 Elsevier | |
| 650 | 7 | |a Immunotherapy |2 Elsevier | |
| 650 | 7 | |a HPV E6 |2 Elsevier | |
| 650 | 7 | |a T cell-based vaccine |2 Elsevier | |
| 650 | 7 | |a HPV E7 |2 Elsevier | |
| 700 | 1 | |a Farmer, Emily |4 oth | |
| 700 | 1 | |a Lin, John |4 oth | |
| 700 | 1 | |a Wu, T.-C. |4 oth | |
| 700 | 1 | |a Hung, Chien-Fu |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Shimura, Tsutomu ELSEVIER |t AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells |d 2014 |d an international journal of molecular and cellular virology |g Amsterdam [u.a.] |w (DE-627)ELV012046744 |
| 773 | 1 | 8 | |g volume:231 |g year:2017 |g day:2 |g month:03 |g pages:148-165 |g extent:18 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.virusres.2016.12.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 231 |j 2017 |b 2 |c 0302 |h 148-165 |g 18 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
a y ay |
|---|---|
| matchkey_str |
yangandrewfarmeremilylinjohnwutchungchie:2017----:hcretttoteaetcntelaevcieaant |
| hierarchy_sort_str |
2017 |
| publishDate |
2017 |
| allfields |
10.1016/j.virusres.2016.12.002 doi GBV00000000000031.pica (DE-627)ELV030349621 (ELSEVIER)S0168-1702(16)30556-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 540 VZ Yang, Andrew verfasserin aut The current state of therapeutic and T cell-based vaccines against human papillomaviruses 2017 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed. Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier HPV E6 Elsevier T cell-based vaccine Elsevier HPV E7 Elsevier Farmer, Emily oth Lin, John oth Wu, T.-C. oth Hung, Chien-Fu oth Enthalten in Elsevier Science Shimura, Tsutomu ELSEVIER AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells 2014 an international journal of molecular and cellular virology Amsterdam [u.a.] (DE-627)ELV012046744 volume:231 year:2017 day:2 month:03 pages:148-165 extent:18 https://doi.org/10.1016/j.virusres.2016.12.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 231 2017 2 0302 148-165 18 045F 610 |
| spelling |
10.1016/j.virusres.2016.12.002 doi GBV00000000000031.pica (DE-627)ELV030349621 (ELSEVIER)S0168-1702(16)30556-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 540 VZ Yang, Andrew verfasserin aut The current state of therapeutic and T cell-based vaccines against human papillomaviruses 2017 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed. Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier HPV E6 Elsevier T cell-based vaccine Elsevier HPV E7 Elsevier Farmer, Emily oth Lin, John oth Wu, T.-C. oth Hung, Chien-Fu oth Enthalten in Elsevier Science Shimura, Tsutomu ELSEVIER AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells 2014 an international journal of molecular and cellular virology Amsterdam [u.a.] (DE-627)ELV012046744 volume:231 year:2017 day:2 month:03 pages:148-165 extent:18 https://doi.org/10.1016/j.virusres.2016.12.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 231 2017 2 0302 148-165 18 045F 610 |
| allfields_unstemmed |
10.1016/j.virusres.2016.12.002 doi GBV00000000000031.pica (DE-627)ELV030349621 (ELSEVIER)S0168-1702(16)30556-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 540 VZ Yang, Andrew verfasserin aut The current state of therapeutic and T cell-based vaccines against human papillomaviruses 2017 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed. Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier HPV E6 Elsevier T cell-based vaccine Elsevier HPV E7 Elsevier Farmer, Emily oth Lin, John oth Wu, T.-C. oth Hung, Chien-Fu oth Enthalten in Elsevier Science Shimura, Tsutomu ELSEVIER AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells 2014 an international journal of molecular and cellular virology Amsterdam [u.a.] (DE-627)ELV012046744 volume:231 year:2017 day:2 month:03 pages:148-165 extent:18 https://doi.org/10.1016/j.virusres.2016.12.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 231 2017 2 0302 148-165 18 045F 610 |
| allfieldsGer |
10.1016/j.virusres.2016.12.002 doi GBV00000000000031.pica (DE-627)ELV030349621 (ELSEVIER)S0168-1702(16)30556-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 540 VZ Yang, Andrew verfasserin aut The current state of therapeutic and T cell-based vaccines against human papillomaviruses 2017 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed. Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier HPV E6 Elsevier T cell-based vaccine Elsevier HPV E7 Elsevier Farmer, Emily oth Lin, John oth Wu, T.-C. oth Hung, Chien-Fu oth Enthalten in Elsevier Science Shimura, Tsutomu ELSEVIER AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells 2014 an international journal of molecular and cellular virology Amsterdam [u.a.] (DE-627)ELV012046744 volume:231 year:2017 day:2 month:03 pages:148-165 extent:18 https://doi.org/10.1016/j.virusres.2016.12.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 231 2017 2 0302 148-165 18 045F 610 |
| allfieldsSound |
10.1016/j.virusres.2016.12.002 doi GBV00000000000031.pica (DE-627)ELV030349621 (ELSEVIER)S0168-1702(16)30556-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 540 VZ Yang, Andrew verfasserin aut The current state of therapeutic and T cell-based vaccines against human papillomaviruses 2017 18 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed. Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier HPV E6 Elsevier T cell-based vaccine Elsevier HPV E7 Elsevier Farmer, Emily oth Lin, John oth Wu, T.-C. oth Hung, Chien-Fu oth Enthalten in Elsevier Science Shimura, Tsutomu ELSEVIER AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells 2014 an international journal of molecular and cellular virology Amsterdam [u.a.] (DE-627)ELV012046744 volume:231 year:2017 day:2 month:03 pages:148-165 extent:18 https://doi.org/10.1016/j.virusres.2016.12.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 231 2017 2 0302 148-165 18 045F 610 |
| language |
English |
| source |
Enthalten in AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells Amsterdam [u.a.] volume:231 year:2017 day:2 month:03 pages:148-165 extent:18 |
| sourceStr |
Enthalten in AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells Amsterdam [u.a.] volume:231 year:2017 day:2 month:03 pages:148-165 extent:18 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Human papillomavirus Therapeutic vaccine Immunotherapy HPV E6 T cell-based vaccine HPV E7 |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells |
| authorswithroles_txt_mv |
Yang, Andrew @@aut@@ Farmer, Emily @@oth@@ Lin, John @@oth@@ Wu, T.-C. @@oth@@ Hung, Chien-Fu @@oth@@ |
| publishDateDaySort_date |
2017-01-02T00:00:00Z |
| hierarchy_top_id |
ELV012046744 |
| dewey-sort |
3610 |
| id |
ELV030349621 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030349621</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623204630.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.virusres.2016.12.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000031.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030349621</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-1702(16)30556-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yang, Andrew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The current state of therapeutic and T cell-based vaccines against human papillomaviruses</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Human papillomavirus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapeutic vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HPV E6</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">T cell-based vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HPV E7</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Farmer, Emily</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lin, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, T.-C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hung, Chien-Fu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Shimura, Tsutomu ELSEVIER</subfield><subfield code="t">AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells</subfield><subfield code="d">2014</subfield><subfield code="d">an international journal of molecular and cellular virology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012046744</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:231</subfield><subfield code="g">year:2017</subfield><subfield code="g">day:2</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:148-165</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.virusres.2016.12.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">231</subfield><subfield code="j">2017</subfield><subfield code="b">2</subfield><subfield code="c">0302</subfield><subfield code="h">148-165</subfield><subfield code="g">18</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Yang, Andrew |
| spellingShingle |
Yang, Andrew ddc 610 ddc 570 Elsevier Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier HPV E6 Elsevier T cell-based vaccine Elsevier HPV E7 The current state of therapeutic and T cell-based vaccines against human papillomaviruses |
| authorStr |
Yang, Andrew |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV012046744 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 570 540 VZ The current state of therapeutic and T cell-based vaccines against human papillomaviruses Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier HPV E6 Elsevier T cell-based vaccine Elsevier HPV E7 Elsevier |
| topic |
ddc 610 ddc 570 Elsevier Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier HPV E6 Elsevier T cell-based vaccine Elsevier HPV E7 |
| topic_unstemmed |
ddc 610 ddc 570 Elsevier Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier HPV E6 Elsevier T cell-based vaccine Elsevier HPV E7 |
| topic_browse |
ddc 610 ddc 570 Elsevier Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier HPV E6 Elsevier T cell-based vaccine Elsevier HPV E7 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e f ef j l jl t c w tcw c f h cfh |
| hierarchy_parent_title |
AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells |
| hierarchy_parent_id |
ELV012046744 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV012046744 |
| title |
The current state of therapeutic and T cell-based vaccines against human papillomaviruses |
| ctrlnum |
(DE-627)ELV030349621 (ELSEVIER)S0168-1702(16)30556-1 |
| title_full |
The current state of therapeutic and T cell-based vaccines against human papillomaviruses |
| author_sort |
Yang, Andrew |
| journal |
AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells |
| journalStr |
AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
148 |
| author_browse |
Yang, Andrew |
| container_volume |
231 |
| physical |
18 |
| class |
610 610 DE-600 610 VZ 570 540 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Yang, Andrew |
| doi_str_mv |
10.1016/j.virusres.2016.12.002 |
| dewey-full |
610 570 540 |
| title_sort |
current state of therapeutic and t cell-based vaccines against human papillomaviruses |
| title_auth |
The current state of therapeutic and T cell-based vaccines against human papillomaviruses |
| abstract |
• HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed. |
| abstractGer |
• HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed. |
| abstract_unstemmed |
• HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
The current state of therapeutic and T cell-based vaccines against human papillomaviruses |
| url |
https://doi.org/10.1016/j.virusres.2016.12.002 |
| remote_bool |
true |
| author2 |
Farmer, Emily Lin, John Wu, T.-C. Hung, Chien-Fu |
| author2Str |
Farmer, Emily Lin, John Wu, T.-C. Hung, Chien-Fu |
| ppnlink |
ELV012046744 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.virusres.2016.12.002 |
| up_date |
2024-07-06T17:21:27.877Z |
| _version_ |
1803851124315258880 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030349621</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623204630.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.virusres.2016.12.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000031.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030349621</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0168-1702(16)30556-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yang, Andrew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The current state of therapeutic and T cell-based vaccines against human papillomaviruses</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• HPV is a causal factor for multiple cancers and diseases. • Preventative HPV vaccine is not effective at clearing preexisting infections. • Therapeutic and T cell based HPV vaccines typically target oncoproteins E6 and E7. • Several clinical trials have been performed to assess the efficacy of the vaccines. • More trials are expected as new strategies to enhance vaccine potency are developed.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Human papillomavirus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapeutic vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HPV E6</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">T cell-based vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HPV E7</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Farmer, Emily</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lin, John</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, T.-C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hung, Chien-Fu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Shimura, Tsutomu ELSEVIER</subfield><subfield code="t">AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells</subfield><subfield code="d">2014</subfield><subfield code="d">an international journal of molecular and cellular virology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012046744</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:231</subfield><subfield code="g">year:2017</subfield><subfield code="g">day:2</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:148-165</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.virusres.2016.12.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">231</subfield><subfield code="j">2017</subfield><subfield code="b">2</subfield><subfield code="c">0302</subfield><subfield code="h">148-165</subfield><subfield code="g">18</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.400923 |